Jupiter Life Line Hospitals Ltd

Jupiter Life Line Hospitals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure will be effective from October 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter and half-year ending September 30, 2026. The company is implementing this measure in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and its internal code of conduct. The National Securities Depository Limited will facilitate this by freezing PAN at the security level for the company's ISIN.

Jupiter Life Line Hospitals Ltd has updated its regulatory filings concerning the determination of materiality for events or information. As per Regulation 30(5) of the Listing Regulations, the Board of Directors, in a meeting held on July 31, 2026, has authorized Mr. Harshad Purani, the Chief Financial Officer, to join Dr. Ankit Thakker, the Managing Director & CEO, in this crucial decision-making process. This expands the authority for determining the materiality of events and information. Ms. Suma Upparatti, Company Secretary and Compliance Officer, remains authorized for making disclosures to the stock exchanges. The company will make this information available on its website.

Jupiter Life Line Hospitals Ltd announced that its subsidiary, Jupiter Hospital Pharmacy Private Limited (JHPPL), has acquired 100% of the equity share capital of Sulcus Private Limited for a consideration of ₹3.78 crore. This acquisition makes Sulcus a wholly owned subsidiary of JHPPL and a step-down subsidiary of Jupiter Life Line Hospitals. The company's Board of Directors also approved the unaudited financial results for the quarter ended June 30, 2026, and the appointment of Mr. Harshad Purani as the Chief Financial Officer.

Jupiter Life Line Hospitals Ltd announced a change in management and a significant subsidiary acquisition following its Board of Directors meeting on July 31, 2026. Mr. Harshad Purani has been appointed as the new Chief Financial Officer and Key Managerial Personnel, effective immediately. In a strategic move, Jupiter Hospital Pharmacy Private Limited (JHPPL), a subsidiary, acquired 100% of Sulcus Private Limited for ₹3.78 crore, making Sulcus a wholly owned step-down subsidiary. The board also approved the unaudited financial results for the quarter ended June 30, 2026, along with the Limited Review Report. The company's website will host the details of these announcements.

Jupiter Life Line Hospitals Ltd announced the outcome of its Board Meeting held on July 31, 2026. The board considered and approved the unaudited financial results for the quarter ended June 30, 2026, on both standalone and consolidated bases, along with the limited review report. Additionally, the company appointed Mr. Harshad Purani as the Chief Financial Officer and Key Managerial Personnel, effective July 31, 2026. The board also noted that its subsidiary, Jupiter Hospital Pharmacy Private Limited (JHPPL), acquired 100% of Sulcus Private Limited for ₹3.78 crore, making Sulcus a wholly-owned step-down subsidiary.

Jupiter Life Line Hospitals delivered a classic greenfield-expansion quarter for Q1 FY27: strong topline, shrinking bottom line. Consolidated revenue rose 18.2% YoY to ₹410.98 Cr, but net profit fell 14.5% YoY to ₹37.51 Cr (₹37.49 Cr to owners) and slipped 23% sequentially from Q4's ₹48.76 Cr. EPS came in at ₹5.72 versus ₹6.69 a year ago. With no exceptional items on either side of the comparison, the reported decline is the underlying decline — this is a genuine profit contraction, not an optics effect. The margin bridge is entirely on the cost side of the new-capacity ramp. The Dombivli hospital, commercialised in February 2026, is now in its first full cost-bearing quarter, and the fixed-cost load of new beds is landing before their revenue matures. Consolidated finance costs jumped 55% YoY to ₹12.86 Cr and depreciation rose 25% to ₹26.44 Cr, while employee, professional and other operating expenses each grew 20-26% — outpacing the 16% growth in reported operating revenue. The result: EBITDA margin (OPM) compressed to roughly 19.3% from about 22.5% a year ago, and net margin fell to ~8.9% from ~12.2%. PBT actually declined 18% YoY even as revenue expanded. Against management's own last-call guidance, the picture is two-sided: the confident revenue-growth-from-expansion thesis is intact (revenue +18% YoY, driven by the new-bed ramp toward the ~3,000-bed target across Dombivli, Pune South, Mira Road and BKC), but the near-term margin cost of that asset-heavy model is now visible in the P&L, exactly as the guidance's "Dombivli EBITDA breakeven within two years" caveat implied. No brokerage consensus for the quarter is on record yet — the Q1 FY27 earnings call is scheduled for August 3 — so vsStreet is unmarked. Alongside the numbers, the board named Harshad Purani (a 20-year company veteran) CFO effective July 31, and approved subsidiary JHPPL's ₹3.78 Cr acquisition of Sulcus Private Limited — a backward-integration move to set up an in-house IV-fluids/infusions plant near Ujjain (₹35-40 Cr planned capex over 1-2 years) aimed at lifting pharmacy margins over time.

Catalyst Trusteeship Limited, acting as Debenture Trustee for Jupiter Life Line Hospitals Ltd, has submitted a revised disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The revision corrects an inadvertent error in the previously submitted disclosure dated July 28, 2026. The percentage of pledged holding was mistakenly reported as 30.67% instead of the accurate figure of 5.11%. This error occurred due to the subdivision of equity shares from a face value of ₹10 to ₹2. While the number of pledged shares has adjusted post-stock split, the actual percentage of pledged holding remains unchanged at 5.11%. The revised disclosure confirms the total number of pledged shares post-split is 1,67,59,750, representing 5.11% of the total share capital.

Catalyst Trusteeship Limited, acting as Debenture Trustee, has disclosed the creation of a pledge over 1,67,59,750 equity shares of Jupiter Life Line Hospitals Limited. This represents 25.56% of the total share capital. Prior to this, Catalyst Trusteeship held 33,51,950 shares, representing 5.11% of the share capital, which were also encumbered. Following the pledge, the total encumbered shares held by Catalyst Trusteeship amount to 2,01,11,700, constituting 30.67% of the total share capital. The pledge was created on June 25, 2026.

Jupiter Life Line Hospitals Ltd has announced that its Board of Directors will convene on July 31, 2026. The primary agenda for this meeting is to consider, review, and approve the Unaudited Financial Results, both standalone and consolidated, for the quarter ending June 30, 2026. This includes the Limited Review Report as per SEBI Listing Regulations. Additionally, the company confirmed that the trading window for designated employees and their immediate relatives will remain closed until 48 hours after the declaration of these financial results, a measure in line with the SEBI (Prohibition of Insider Trading) Regulations, 2015. The intimation will also be available on the company's website.

Jupiter Life Line Hospitals Ltd has announced July 24, 2026, as the record date for its equity share sub-division. This corporate action, approved by shareholders at the AGM on July 17, 2026, will split each existing equity share with a face value of ₹10 into five equity shares, each with a face value of ₹2. The new shares will rank pari passu with existing shares. The company has made this information available on its website.